NanoViricides NNVC 深 沪
已收盘 09-26 16:00:00 美东时间
1.42
+0.020
+1.43%
华盛通- 最 高1.42
- 今 开1.40
- 成交量 4.27万股
- 最 低 1.40
- 昨 收 1.40
- 总市值 2282.22万
- 52周最高 1.9195
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 0.94
- 委 比 50.94%
- 总股本 1607.20万
- 历史最高 151.80
- 量 比 0.26
- 振 幅 1.43%
- 历史最低 0.94
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NANO Nuclear Achieves Inclusion In S&P Global Broad Market Index (BMI)
NANO Nuclear Energy Inc. has been included in the S&P Global Broad Market Index (BMI), S&P Total Market Index (TMI), and SPX Completion Index, enhancing its visibility among global institutional investors. The BMI covers 48 countries and over 99% of global market capitalization, while the TMI and Completion Index expand its presence in the U.S. equity market. NANO Nuclear, a leader in advanced nuclear energy, develops clean energy solutions inclu...
09-25 12:30
Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging
<p><p>Nano-X Imaging Ltd.与Monarch Medical Management and Billing LLC达成合作，将在工伤赔偿、疗养院和门诊诊所部署Nano-X的先进成像解决方案。该合作将利用Nano-X.ARC系统、人工智能软件和远程放射学服务，为患者提供更快捷、高质量的诊断服务。</p>
09-18 12:00
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Nanobiotix announced promising results from a Phase 1 study of JNJ-1900 (NBTXR3) for patients with anti-PD-1 resistant primary cutaneous melanoma. The study showed a 47.4% objective response rate, 78.9% disease control rate, and a median overall survival of 14.6 months. The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities reported. These findings suggest that JNJ-1900 could offer a new treatment option for patie...
09-17 20:15
NANO Nuclear Signs Letter of Intent with Cambridge Atom Works to Sell its Portable ODIN™ Reactor Technology
NANO Nuclear Energy Inc. has signed a letter of intent to sell its ODIN™ low-pressure coolant microreactor to Cambridge Atom Works Ltd. for $6.2 million plus future royalties. This strategic move allows NANO Nuclear to focus on its gas-cooled reactor portfolio, including the KRONOS MMR™, LOKI MMR™, and ZEUS™, while capitalizing on the momentum from the Atlantic Partnership for Advanced Nuclear Energy, which aims to streamline nuclear reactor deve...
09-17 12:05
NANO Nuclear to Participate in Upcoming Investor Events
<p>NANO Nuclear Energy Inc. announced its participation in three upcoming investor events: H.C. Wainwright’s 27th Annual Global Investment Conference on September 8th, Benchmark’s Nuclear Innovation Summit on September 16th, and TD Cowen’s 10th Annual Nuclear Fuel Cycle and Next Generation Nuclear Roundtable on October 9th. The company, focused on advanced nuclear energy solutions, operates across five business lines including microreactor techno...
09-05 12:30
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
NANOBIOTIX, a late-clinical stage biotechnology company, announced that its management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The event will take place in New York City at 9:00 am EDT / 3:00 pm CEST. CEO Laurent Levy and CFO Bart van Rhijn will present, with a live webcast available on the Company’s events page, followed by a replay. Nanobiotix, headquartered in Pa...
09-02 20:15
NANO Nuclear Energy Awarded AFWERX Direct to Phase II Contract for KRONOS MMR™ RDT&E at Joint Base Anacostia-Bolling
NANO Nuclear Energy Inc. has been awarded a $1.25 million Direct to Phase II contract by AFWERX to explore deploying its KRONOS MMR™ Energy System at Joint Base Anacostia-Bolling in Washington, D.C. The project aims to enhance energy resilience, reduce reliance on commercial grids, and provide secure, carbon-free power. The KRONOS MMR™ is a high-temperature gas-cooled microreactor designed for safety, autonomy, and multi-decade use.
09-02 11:30
NANO Nuclear Expands Presence in Argentina By Signing Memorandum of Understanding with Dioxitek S.A., Argentina’s Only Uranium Feedstock Manufacturer for Nuclear Fuel Fabrication
NANO Nuclear Energy Inc. has signed a Memorandum of Understanding (MOU) with Dioxitek S.A., an Argentinian nuclear fuel company, to evaluate Argentina's uranium conversion infrastructure and explore collaboration in developing uranium enrichment capabilities. This initiative aims to support Argentina's nuclear supply chain and reduce reliance on foreign suppliers. The MOU aligns with NANO Nuclear's strategic expansion in Argentina and its goal to...
08-27 11:30
Voting Rights and Shares Capital of the Company
Nanobiotix, a late-stage clinical biotechnology company, announced its voting rights and share capital as of July 31, 2025. The company, listed on Euronext Paris and Nasdaq, reported 48,236,671 outstanding shares, with theoretical voting rights totaling 50,340,736 and exercisable voting rights at 50,318,618. Founded in 2003, Nanobiotix specializes in physics-based therapeutic approaches and holds over 25 patent families across oncology, bioavaila...
08-27 06:00
Nano Labs CEO Mr. Kong Jianping Increases Shareholdings by 480,000 Shares, Reaffirming Confidence in Long-Term Growth
Nano Labs Ltd宣布，其董事长兼首席执行官Kong Jianping于8月通过公开市场交易增持了48万股A类普通股，这是继去年5月和9月之后的再次增持。Kong表示对公司的长期增长前景充满信心，并可能在未来考虑进一步增持。Nano Labs是一家领先的Web 3.0基础设施和产品解决方案提供商，专注于高吞吐量计算和高性能计算芯片，并在加密资产领域积极布局。
08-26 10:00
